about
Development and Validation of a New Prognostic System for Patients with Hepatocellular CarcinomaSerum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection.Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease.Epidemiology of thrombocytopenia in patients with chronic hepatitis C: more than meets the eye.Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study.Eltrombopag in patients with chronic liver disease.Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients.Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.Low alpha-fetoprotein HCC and the role of GGTP.Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.Platelet Dysfunction: Status of Thrombopoietin in Thrombocytopenia Associated with Chronic Liver Failure.Economic assessment of eltrombopag in the treatment of thrombocytopenia.12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.Prognostic role of mean platelet volume in patients with cirrhosis.Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.Liver enzyme alteration: a guide for clinicians.A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms.Optimal management of constipation associated with irritable bowel syndromeMELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study.A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis.Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma.Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.Breath Tests to Assess Alcoholic Liver Disease.Common issues in the management of patients in the waiting list and after liver transplantation.Prognosis of untreated hepatocellular carcinoma.Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype.Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.Years of life that could be saved from prevention of hepatocellular carcinoma.Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.Validation of a multivariate model predicting presence and size of varices.Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems.The evolutionary scenario of hepatocellular carcinoma in Italy: an update.
P50
Q28551586-D207AD1F-A748-4434-9121-18D573E33A59Q33344948-E51F7B72-6E31-4F1C-B7AC-20A8C4CE2AC9Q33357794-D6321040-A5D1-4952-AAB0-8FFA298277FBQ33390498-C20A1724-7344-47DC-9A67-4EF7B2DA53D7Q33391639-F13F9BE3-51E3-4972-A37B-5A5F9E5E20F6Q33400529-58A91E66-4D66-48D3-A98C-AE5E018730BFQ33402924-F76A706C-CA76-4EC3-8AA1-632F5E978167Q33403106-2A55A04A-C434-4014-908A-37E60CAE86F9Q33406181-FFEBDA7D-9339-4FCA-9307-E0308E682479Q33407547-F211FEC7-83C5-4D07-94AF-80540A45B50AQ33410939-6C76EF69-9457-4C1B-AA5A-986C75CC2BFFQ33415358-D9598CD0-FC77-491A-8305-4D9D5537FCF0Q33416414-B2D67F79-4398-49F5-97FA-D1BBD9F84FF3Q33421239-2B163CA7-F37D-4F72-87A9-D86256F7C52BQ33423433-23688EB7-024D-4C56-967E-1CFF61CBA9CDQ33424436-83E5C4A5-2A21-4FA1-A14A-CFE82351E006Q33424577-3805194A-AF4F-4172-9BCB-9BCBB3EB19BEQ33428642-9C70DD00-56CB-4AE9-812A-DBCF8705BD40Q33430547-86C66516-02FB-47BA-AF31-8953029D31B9Q33430951-F6D3FBE5-4E34-46EB-9CF5-8FDA324E60A3Q33759637-A737BB95-6207-4D39-B005-E4A549AE0CE1Q34570941-1F9CD4DB-66AE-4A7C-B1A1-46F34838C965Q35586543-0FD28B2E-330D-47C8-88D2-9CCD297277E4Q35595313-343D5F2C-54D1-486F-90F8-BDA2F7627F40Q35677687-E6AB75E9-C44E-4C4D-888C-9CCEFECBBDDEQ37408912-9107CEF1-70D8-4A9D-9AEB-67201521E87CQ38773911-5278F200-BB50-4B32-AF7B-8CD7388EE665Q38789871-831183E4-420D-461B-B71B-52E33EC88A30Q38832073-E062E53F-A6BF-4EC1-AEC3-D7B48BA69DF4Q39092496-729B342A-3C72-4675-A2E8-39BDF2CFB462Q39126855-AE85D0CE-7590-443F-859B-C5CE7631EBAAQ39204902-772AA4D8-1EED-462C-AD10-A8659909DCDDQ39240225-A802BF1A-7C57-4F03-A218-FBBBD5C5AC12Q39748377-1139FE28-9D13-4B93-968C-67A46DDC2201Q40007128-A3D5E40C-0BFE-48BF-A700-72A28680D44CQ40178069-7A14C661-A1A9-49A3-8818-893F95ADD4D1Q40202547-C8E5E7CB-0DFC-48AC-8186-73C6132DC0B4Q40335094-08CF3344-0C1F-4EBA-A076-F5F487DFDACCQ40532246-44A01C62-DC73-4E08-959D-3F3A6F011796Q40646684-7B51B6BD-E6DA-49D0-88DE-8487F0EA72F5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Edoardo G. Giannini
@ast
Edoardo G. Giannini
@en
Edoardo G. Giannini
@es
Edoardo G. Giannini
@sl
type
label
Edoardo G. Giannini
@ast
Edoardo G. Giannini
@en
Edoardo G. Giannini
@es
Edoardo G. Giannini
@sl
altLabel
Edoardo G. Giannini
@en
Edoardo Giovanni Giannini
@en
prefLabel
Edoardo G. Giannini
@ast
Edoardo G. Giannini
@en
Edoardo G. Giannini
@es
Edoardo G. Giannini
@sl
P1053
E-1120-2012
P106
P1153
7101771483
P21
P31
P3829
P3835
edoardo-g-giannini
P496
0000-0001-8526-837X